Antigenic Drift and the 2026–2027 Flu Vaccine: Inside the Science of Annual Strain Updates | iMedic

What Is Antigenic Drift and Why Does It Force Annual Vaccine Reformulation?

Influenza A and B viruses carry two major surface glycoproteins—haemagglutinin (HA) and neuraminidase (NA)—that serve as the primary targets of the human immune response. As these viruses replicate, their RNA-dependent RNA polymerase introduces errors at a relatively high rate, producing a steady stream of variant viruses. Most mutations are neutral or harmful to the virus, but occasionally a change occurs in a key antigenic site on the HA protein that reduces recognition by existing antibodies. When such variants gain a transmission advantage in a population with widespread immunity to older strains, they can become dominant within a season or across consecutive seasons.

The A(H3N2) subtype has historically been the most prone to rapid antigenic drift among seasonal influenza viruses, with major antigenic cluster transitions occurring roughly every three to five years. The HA protein of H3N2 viruses carries multiple glycosylation sites near antigenic regions, and the addition or removal of sugar molecules at these positions can mask or expose epitopes, further complicating immune recognition. For the 2026–2027 cycle, WHO Collaborating Centres documented that circulating A(H3N2) viruses had accumulated substitutions in the HA1 domain that substantially reduced reactivity with ferret antisera raised against the previous vaccine virus—a standard measure of antigenic distance used in strain selection decisions.

How Do Laboratories Measure Whether the Current Vaccine Still Matches Circulating Strains?

The cornerstone laboratory method for assessing vaccine–virus match is the haemagglutination inhibition (HI) assay. In this test, antisera from ferrets infected with the current vaccine virus are mixed with newly isolated field viruses. If the antisera effectively block the new virus from agglutinating red blood cells, the antigenic match is considered adequate. A fourfold or greater reduction in HI titre compared to the homologous vaccine virus traditionally signals meaningful antigenic divergence and triggers consideration of a vaccine update.

Complementing the HI assay, focus reduction neutralization tests (FRNTs) measure the ability of antibodies to prevent actual viral infection of cultured cells, providing a more functionally relevant assessment. Next-generation sequencing of HA and NA genes enables rapid identification of amino acid substitutions at known antigenic sites, often before sufficient virus isolates are available for serological testing. Computational tools such as antigenic cartography—developed by researchers at the University of Cambridge—translate serological data into spatial maps where the distance between points reflects antigenic difference, making it easier to visualize how far new variants have moved from existing vaccine strains. Data from all these methods contributed to the WHO decision in early 2026 that both influenza A vaccine components required updating.

What Does a Dual A-Component Update Mean for Vaccine Effectiveness Expectations?

Vaccine effectiveness (VE) against influenza is highly dependent on the antigenic match between vaccine and circulating strains. During seasons with good match, VE against medically attended illness typically ranges from 40% to 60% in the general population, according to data from the US CDC Flu VE Network and similar surveillance programmes in Europe and Australia. When antigenic drift creates a mismatch—as occurred in several recent A(H3N2)-dominated seasons—VE can drop below 20% for that component.

The simultaneous update of both A(H1N1)pdm09 and A(H3N2) components for 2026–2027 is relatively uncommon. In many years, only one A-component requires change, while the other remains adequately matched. A dual update indicates that both subtypes have undergone sufficient evolution to warrant concern. However, it also presents an opportunity: by incorporating newly matched candidate vaccine viruses for both subtypes, the resulting vaccine has the potential to restore higher levels of protection across influenza A infections. Public health authorities have emphasized that even in seasons with partial mismatch, vaccination reduces the risk of severe outcomes, hospitalisation, and death—benefits that extend beyond the prevention of mild symptomatic illness.